With the continuous development of medical science and technology and the rapid change of modern medical technology, the methods of treating tumors are gradually diversified, and the most effective means to guarantee survival is to choose scientific and reasonable treatment according to the patient’s own situation. Biological therapy technology overcomes the limitations of conventional treatment and is a historical breakthrough in tumor treatment, which is the fourth type of cancer treatment method developed after surgery, radiotherapy and chemotherapy. Biological cell therapy is to collect a small number of patients’ own multiple key immune cells (CIK cells, DC cells), use immune-enhancing factors in the GMP laboratory to activate the patient’s immune cells, expand them, and then infuse them back into the patient’s body, so that it can fundamentally change the growth environment of the tumor cells to inhibit the growth and value-added of the tumor, and achieve the therapeutic method to kill the tumor and inhibit the tumor from recurring and metastasizing. Early-stage tumor patients: Biotherapy can kill tumor cells and improve the success rate of recovery. Post-operative patients: Biotherapy can remove residual tumor cells, prevent metastasis and ensure long-term survival with tumor. For combined treatment: Biotherapy can combine with surgery, radiotherapy and chemotherapy to reduce the toxic side effects and enhance the therapeutic effect. For those who cannot bear surgery, radiotherapy and chemotherapy, biological therapy is safe, efficient and can control the disease. People with advanced tumors: biological therapy can prolong the survival time, improve the quality of life, and nearly double the 5-year survival rate. Biological cell therapy is applicable to a variety of solid tumors, including malignant melanoma, prostate cancer, kidney cancer, bladder cancer, ovarian cancer, colon cancer, rectal cancer, breast cancer, cervical cancer, lung cancer, laryngeal cancer, nasopharyngeal carcinoma, pancreatic cancer, hepatocellular carcinoma, gastric cancer, and other solid tumors to prevent recurrence after surgery, and it can also be used for the recurrence of hematological malignant tumors, such as multiple myeloma, B-lymphoma, and leukemia, for the majority of the cells For the majority of cellular immunotherapy applicants, it can also be used for further consolidation treatment of the above tumors to prolong the survival period, improve the quality of life and inhibit the deterioration of tumors.